glp-1 drugs in development Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment What is the pipeline for

We measure the odds ratio of developing pancreatitis between patients who have taken a large cumulative dose of GLP-1 agonist and those with a low cumulative dose of GLP-1 agonist

These reports form the basis of allegations that some users experienced debilitating symptoms after taking medications intended to treat diabetes and promote weight loss

And the effect of liraglutide might be associated with improvement of BBB glucose transport capacity (244)

These medications may not be suitable if you have severe gastroparesis, active eating disorders, extreme frailty with low BMI, or very limited life expectancy

FDA-approved for type 2 diabetes and for reducing the risk of major adverse cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease